Anti-CCM2 antibody produced in goat
SIGMA/SAB2500214 - affinity isolated antibody, buffered aqueous solution
Synonym: Anti-C7orf22; Anti-Cerebral cavernous malformation 2; Anti-MGC4067; Anti-MGC4607; Anti-MGC74868
Product Type: Chemical
SAB2500214 (0.5μg/ml) staining of Human (A) and Rat (B) Duodenum lysate (35μg protein in RIPA buffer). Detected by chemiluminescence.
SAB2500214 Flow cytometric analysis of paraformaldehyde fixed A431 cells (blue line), permeabilized with 0.5% Triton. Primary incubation 1hr (10ug/ml) followed by Alexa Fluor 488 secondary antibody (1ug/ml). IgG control: Unimmunized goat IgG (black line) followed by Alexa Fluor 488 secondary antibody.
SAB2500214 (0.5μg/ml) staining of HeLa (A) and (1ug/ml) NIH3T3 (B) cell lysate (RIPA buffer, (35μg protein in RIPA buffer). Detected by chemiluminescence.
SAB2500214 (1ug/ml) staining of A431 (A) and HeLa (B), (2ug/ml) HEK293 (C) and (0.1ug/ml) MCF7 (D), NIH3T3 (E), KNRK (F) and MDCK (G) cell lysate (35μg protein in RIPA buffer). Detected by chemiluminescence.
Immunoblotting Anti-CCM2: Cat. No. SAB2500214: (0.03 μg/mL) staining of Human Heart lysate (35 μg protein in RIPA buffer). Primary incubation was 1 hour. Detected by chemiluminescence.
| antibody form | affinity isolated antibody |
| antibody product type | primary antibodies |
| biological source | goat |
| clone | polyclonal |
| conjugate | unconjugated |
| form | buffered aqueous solution |
| Quality Level | 100  |
| shipped in | dry ice |
| species reactivity | rat, human, mouse, canine |
| storage temp. | −20°C |
| target post-translational modification | unmodified |
| technique(s) | indirect ELISA: suitable |
| western blot: suitable | |
| UniProt accession no. | Q9BSQ5  |
| Application: | Anti-CCM2 antibody produced in goat is suitable for indirect ELISA and western blot assay. |
| Biochem/physiol Actions: | Cerebral cavernous malformation 2 (CCM2) is associated with several cellular pathways. It mainly behaves as a scaffold protein in the activation of GTPase Rac-dependent p38 mitogen-activated protein kinase (MAPK) during hyperosmotic stress. It also participates in vascular integrity. CCM2 may play a role in vasculogenesis and angiogenesis during the development of the brain. Mutation in the gene is associated with familial cerebral cavernous malformations. |
| Features and Benefits: | Evaluate our antibodies with complete peace of mind. If the antibody does not perform in your application, we will issue a full credit or replacement antibody. Learn more. |
| General description: | Cerebral cavernous malformation 2 (CCM2) is an adaptor protein consisting of two domains. Structurally, it has two domains, N-terminal phosphotyrosine-binding (PTB) domain and an independent domain named as Karet domain at the C-terminal end. It is mapped on human chromosome 7p. Its phosphotyrosine-binding (PTB) domain has the ability to bind proteins. It is expressed in vascular endothelium and neuroglial precursor cells during development and also observed in arterial endothelium, neurons, and some of the glial cells in adult neocortex. |
| Immunogen: | Peptide with sequence C-KGEKSRDKKAHEK from the internal region of the protein sequence according to NP_001025006.1; NP_113631.1. |
| Physical form: | Supplied at 0.5 mg/mL in Tris saline with 0.02% sodium azide and 0.5% bovine serum albumin. |
| Symbol |  GHS07 |
| Signal word | Warning |
| Hazard statements | H315 - H319 |
| Precautionary statements | P305 + P351 + P338 |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 2 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Storage Temp. | −20°C |
| UNSPSC | 12352203 |